Danish Firm Bavarian Nordic Boosts Mpox Vaccine Production Amid Public Health Emergency

Danish biotech company Bavarian Nordic is set to increase the production of its mpox vaccine. The firm will collaborate with international health organizations to ensure equitable distribution, as the disease is now a global public health emergency. They aim to produce 10 million doses by 2025 and supply 2 million doses this year.

Danish biotech firm Bavarian Nordic announced plans to significantly ramp up its production of the mpox vaccine. The move comes in response to the declaration of mpox as a global public health emergency.

The company has informed the Africa Centres for Disease Control and Prevention (CDC) that it can manufacture 10 million doses by the end of 2025, with 2 million doses available this year. Efforts are underway to broaden its production network to include Africa, ensuring all countries have access to the vaccine.

WHO recently declared mpox a global emergency, marking the virus's second such designation in two years. With 27,000 cases and over 1,100 deaths reported in Congo since January 2023, the urgency to control the viral infection, which manifests in pus-filled lesions and flu-like symptoms, has intensified.

(With inputs from agencies.)